Compounds > medroxyprogesterone acetate
Page last updated: 2024-08-17

medroxyprogesterone acetate and Minimal Disease, Residual

medroxyprogesterone acetate has been researched along with Minimal Disease, Residual in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's1 (25.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Benson, JR; Dumitru, D; Jatoi, I1
Cho, A; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Lee, SW; Park, JY; Suh, DS1
Cade, TJ; Neesham, D; Quinn, MA; Rome, RM1
Fujii, S; Kato, K; Konishi, I; Mitsushita, J; Toki, T1

Reviews

1 review(s) available for medroxyprogesterone acetate and Minimal Disease, Residual

ArticleYear
Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate.
    Gynecologic oncology, 2000, Volume: 79, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Neoplasm, Residual; Pregnancy; Pregnancy Complications, Neoplastic

2000

Other Studies

3 other study(ies) available for medroxyprogesterone acetate and Minimal Disease, Residual

ArticleYear
Highlights of the San Antonio Breast Cancer Symposium 2019 Part 1: the challenges of tumor heterogeneity.
    Future oncology (London, England), 2020, Volume: 16, Issue:21

    Topics: Breast Neoplasms; Early Detection of Cancer; Estrogens, Conjugated (USP); Female; Humans; Image-Guided Biopsy; Magnetic Resonance Imaging; Mammography; Medroxyprogesterone Acetate; Neoplasm, Residual; Postmenopause; Radiotherapy; Tumor Microenvironment

2020
Continued medical treatment for persistent early endometrial cancer in young women.
    Gynecologic oncology, 2021, Volume: 160, Issue:2

    Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Biopsy; Carcinoma, Endometrioid; Disease-Free Survival; Drug Administration Schedule; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Fertility Preservation; Follow-Up Studies; Humans; Intrauterine Devices; Levonorgestrel; Magnetic Resonance Imaging; Medroxyprogesterone Acetate; Megestrol Acetate; Myometrium; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome; Ultrasonography

2021
Progestogen treatment options for early endometrial cancer.
    BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:7

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Curettage; Endometrial Neoplasms; Female; Humans; Hysterectomy; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Middle Aged; Neoplasm, Residual; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Retrospective Studies; Treatment Outcome; Young Adult

2010